Corsair Capital Management L.P. Trims Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Corsair Capital Management L.P. lowered its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 31.3% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 21,920 shares of the medical research company’s stock after selling 9,975 shares during the quarter. IQVIA makes up approximately 1.2% of Corsair Capital Management L.P.’s holdings, making the stock its 20th biggest position. Corsair Capital Management L.P.’s holdings in IQVIA were worth $5,194,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Advisors Asset Management Inc. increased its holdings in IQVIA by 106.4% in the 1st quarter. Advisors Asset Management Inc. now owns 1,298 shares of the medical research company’s stock worth $328,000 after acquiring an additional 669 shares in the last quarter. B. Riley Wealth Advisors Inc. increased its holdings in IQVIA by 13.9% in the 1st quarter. B. Riley Wealth Advisors Inc. now owns 3,568 shares of the medical research company’s stock worth $902,000 after acquiring an additional 436 shares in the last quarter. Tidal Investments LLC increased its holdings in IQVIA by 101.9% in the 1st quarter. Tidal Investments LLC now owns 7,637 shares of the medical research company’s stock worth $1,931,000 after acquiring an additional 3,854 shares in the last quarter. Comerica Bank increased its holdings in IQVIA by 2.9% in the 1st quarter. Comerica Bank now owns 41,440 shares of the medical research company’s stock worth $10,480,000 after acquiring an additional 1,161 shares in the last quarter. Finally, Plato Investment Management Ltd increased its holdings in IQVIA by 12,737.5% in the 1st quarter. Plato Investment Management Ltd now owns 4,108 shares of the medical research company’s stock worth $1,039,000 after acquiring an additional 4,076 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 1.4 %

Shares of IQV opened at $203.99 on Wednesday. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The business has a fifty day moving average of $221.18 and a 200 day moving average of $226.75. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a market cap of $37.02 billion, a PE ratio of 26.41, a P/E/G ratio of 2.10 and a beta of 1.51.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Leerink Partners reissued an “outperform” rating and issued a $248.00 target price (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Royal Bank of Canada restated an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a research note on Friday, November 1st. BTIG Research dropped their price target on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Evercore ISI dropped their price target on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Finally, Robert W. Baird dropped their price target on IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a research note on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average price target of $256.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.